# Glycoprotein in Immunotherapy Response and Efficacy Prediction of Lung Cancer

> **NCT06730503** · — · RECRUITING · sponsor: **Shanghai Chest Hospital** · enrollment: 250 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Immune checkpoint inhibitor

## Key facts

- **NCT ID:** NCT06730503
- **Lead sponsor:** Shanghai Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-01
- **Primary completion:** 2027-10-31
- **Final completion:** 2028-10-31
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2024-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06730503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06730503, "Glycoprotein in Immunotherapy Response and Efficacy Prediction of Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06730503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*